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ABSTRACT
Purpose CriticalSorb™, with the principal component Solutol®
HS15, is a novel mucosal drug delivery system demonstrated to
improve the bioavailability of selected biotherapeutics. The inten-
tion of this study is to elucidate mechanism(s) responsible for the
enhancement of trans-mucosal absorption of biological drugs by
Solutol® HS15.
Methods Micelle size and CMC of Solutol® HS15 were deter-
mined in biologically relevant media. Polarised airway Calu-3 cell
layers were used to measure the permeability of a panel of
biological drugs, and to assess changes in TEER, tight junction
and F-actin morphology. The rate of cell endocytosis was mea-
sured in vitro in the presence of Solutol® HS15 using a mem-
brane probe, FM 2–10.
Results This work initially confirms surfactant-like behaviour of
Solutol®HS15 in aqueous media, while subsequent experiments
demonstrate that the effect of Solutol® HS15 on epithelial tight
junctions is different from a ‘classical’ tight junction opening agent
and illustrate the effect of Solutol® HS15 on the cell membrane
(endocytosis rate) and F-actin cytoskeleton.
Conclusion Solutol® HS15 is the principle component of
CriticalSorb™ that has shown an enhancement in permeability
of medium sized biological drugs across epithelia. This study
suggests that its mechanism of action arises primarily from effects
on the cell membrane and consequent impacts on the cell cyto-
skeleton in terms of actin organisation and tight junction opening.
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INTRODUCTION
The potential benefit of delivering biological drugs across
the mucosa as opposed to via the parenteral route has
attracted considerable attention, particularly as advances in
biotechnology have now created a capacity to produce
biologically active macromolecules (‘biologics’) on a com-
mercial scale. However, the ability of these molecules (pro-
teins, antibodies or nucleic acids) to cross the mucosa is
normally poor, resulting in systemic bioavailabilities that
are typically sub-optimal for therapeutic purposes (1,2),
and have evolved to present a barrier to the movement of
material from external environments into the systemic cir-
culation. Hence, the development of a biological drug from
a new compound stage to a marketed product is dependent
on the development of appropriate formulations. Different
approaches have been investigated to improve the absorp-
tion and the resulting bioavailability of biological drugs
following mucosal administration, including manipulation
of the formulation and/or co-administration with agents that
improve its transport across the mucosa (absorption en-
hancers) (3). The term ‘absorption enhancer’ incorporates
chemically diverse compounds, ranging from surfactants,
polymers, chelating agents, and enzymes, which exert their
absorption enhancing effect through different mechanisms.
The action of permeability enhancers has been attributed to
effects on the cell membrane fluidity (exerted by surfactant-
type molecules and fatty acids), thereby enhancing drug
delivery via the transcellular route (4, 5), or alterations in
junctional proteins caused by, for example chitosan (6, 7),
resulting in promotion of drug translocation through the
paracellular route.
CriticalSorb® is a novel absorption enhancing formula-
tion that contains Macrogol 15 hydroxy stearate (Solutol®
HS15) (Fig. 1) as the principal component, proposed to act
as a permeability enhancer. CriticalSorb® technology is
currently in early clinical development stage as a nasal spray
formulation for delivery of human growth hormone, based
on a previously demonstrated enhancement of the bioavail-
ability of human growth hormone and insulin in both ani-
mal studies and human trials (8). In addition, Solutol®
HS15 is currently used to increase the aqueous solubility
of Biopharmaceutical Classification System (BCS) Class 2
and 4 lipophilic molecules (9).
This study is based on the previously demonstrated ability
of CriticalSorb® to increase the permeation of 14C-mannitol
and FITC-dextran 4,000 Da through Caco-2 cell monolayers
and rat colonic mucosa (10), and aims to ascertain the mech-
anism (s) of absorption enhancement of Solutol®HS15, as the
key component of CriticalSorb®. Understanding the mecha-
nism of action will be important in the assessment of the
absorption enhancing capacity of Solutol® HS15 and identi-
fying the bioactives compatible with and amenable to its
absorption enhancing action.
The work initially set out to investigate the critical
micelle concentration and micelle hydrodynamic radii of
Solutol® HS15 in aqueous media. Subsequent experi-
ments assessed if Solutol® HS15 resulted in cytotoxic
effects on a panel of epithelial cells (A549, Calu-3 and
Caco-2) using a typical cell metabolic activity assay
(MTS) and the lactate dehydrogenase (LDH) assay.
Experiments then focused on establishing the ability of
Solutol® HS15 to enhance the permeability of model
proteins across confluent Calu-3 monolayers at 37 and
4°C, at the same time probing the permeability-
promoting mechanism of action. To ascertain whether
Solutol® HS15 operates via a transcellular or paracellular
mechanism of action, the effect of its application on
transepithelial electrical resistance (TEER), zonula
occludens-1 and F-actin staining, as well as the recycling
rate of a membrane dye was also investigated.
MATERIALS AND METHODS
Materials
Solutol® HS15 was provided by Critical Pharmaceuticals
(Nottingham, UK) and was obtained originally from BASF.
Pyrene, phosphate buffered saline (PBS: 1X), Eagle’s
Minimum Essential Medium (EMEM), Foetal Bovine Serum
(FBS), L-Glutamine, Trypsin/EDTA, Hank’s Balanced Salt
Solution (HBSS), Non-essential amino acids (NEAA), Sodium
Pyruvate, and Fluorescein isothiocyanate-insulin were pur-
chased from Sigma, UK. Alexafluor564-Phallodin, mouse
anti-zonula occludens (ZO)-1 primary antibody, goat, anti-
mouse secondary antibody (FITC-labelled) and (N-(3-
Triethylammoniumpropyl)-4-(4-(diethylamino)styryl)
Fig. 1 Principle component of
CriticalSorb™ (Critical
Pharmaceuticals, Nottingham, UK),
Solutol ® HS15; a mixture of
Polyglycol mono- and di-esters of
12 hydroxystearic acid. Taken from
(21).
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Pyridinium Dibromide (FM2-10) were purchased from
Invitrogen, UK.
Transwell® 12-well inserts of 0.4 μm pore size and 12 mm
diameter, and 96 well plates were purchased from Costar,
Corning NY. Transepithelial electrical resistance (TEER) of
Calu-3 cell monolayers was measured using an epithelial
voltohmmeter (EVOM, World Precision Instruments, USA).
Absorbance was read using an MFX plate reader (Dynex,
USA) and fluorescence read using a Dynex MFX microtiter
plate fluorometer (Dynex, USA).
Determination of CMC and Particle Size of Solutol®
HS15
The critical micelle concentration (CMC) of Solutol® HS15
was determined using the unique emission spectrum of
pyrene. Emission peaks 1 and 3 were normalised to give an
indication of the polarity of pyrene microenvironment (exci-
tation at 337 nm, emission normalised 373/383 nm). 40 mg
pyrene was solubilised in a 20:80 propanol:water solution and
then diluted to achieve a 2 μM solution in water, PBS and
H B S S [ s u p p l e m e n t e d w i t h 2 5 mM 4 - ( 2 -
Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES),
pH 7.0] at room temperature (21°C). The working pyrene
solution was added to Solutol® HS15 solutions with concen-
trations ranging from 0.001 to 10.0 mM. These were excited
at 337 nm and the resulting fluorescence emission measured
on a Hitachi, model f4500 fluorescence spectrophotometer
with 2.5 nm ex/em slit width. The CMC can then be deter-
mined when emission peaks 1 and 3 are normalised which
indicates the micropolarity of pyrene. Normalised values
greater than 1 indicate pyrene is in a hydrophilic environment
and normalised values below 1 indicate pyrenes environment
to be in a hydrophobic environment.
The micellar hydrodynamic radius of Solutol® HS15 was
characterised by dynamic light scattering (DLS) using a
Viscotek 802 system (Malvern, UK) at concentrations of
0.010, 0.10, 1.0 and 10.0 mM in 0.2 μm filtered 25 mM
HEPES buffer (pH 7.4) at room temperature and 37°C.
Triton X-100 was used to confirm the accuracy and reliability
of DLS when determining micelle size.
Cell Culture
Calu-3 human bronchial carcinoma cells were purchased
from the American Type Culture Collection (ATCC, USA)
and were used at a passage range of 20–40 for all experiments.
The Calu-3 cell line was used as an in vitro model of the
airways. This cell line is derived from human bronchial sub-
mucosal glands and, while it does not model pulmonary
alveolar type I or type II cells, it is the most often used airway
epithelial model (11, 12). Cells were maintained at 37°C, 5%
CO2 in liquid-covered culture in Eagle’s Minimum Essential
Medium (EMEM) supplemented with 10%v/v FBS, 1%w/v
L-glutamine, 1%w/v sodium pyruvate and 1%w/v non-
essential amino acids.
K562 myelogenous leukemia cell line was obtained from
the European Collection of Cell Cultures; the cells were used
between passages 20–30. K562 cells were maintained at 37°C
and 5%CO2 as a suspension culture in RPMI-1640 medium,
supplemented with 10% FBS and 1%w/vL-Glutamine. Cells
were grown to confluence in a 500 mL culture flask.
Cell Viability Assays
For bothMTS and LDH cell viability assays, cells were seeded
at a density of 1×104 cells on 96-well plates (Nunclon 96 Flat
Bottom) and cultured for a minimum of 24 h. Solutol® HS15
(in 25 mM HBSS:HEPES, pH 7.4) solutions were applied at
concentrations above and below the CMC (0.01 mM–
20 mM) and cytotoxicity was determined using the MTS
and LDH assays. 25 mM HBSS:HEPES was used as a nega-
tive control and Triton-X 100 (3 mM) as a positive control.
Following 3 h incubation, the MTS reagent in media and
LDH working solution were added to the cells (following the
manufacturers’ instructions) and the cells were incubated for a
further 3 h at 37°C. Thereafter, absorbance was measured at
492 nm using a 96-well MFX plate reader (Dynex).
Relative cell metabolic activity was calculated using:
Relative matabolic activity %ð Þ
¼ Sample absorption−TritonX 100absorption
HBSS : HEPES absorption−TritonX 100absorption
 100
Relative LDH release was calculated using;
Relative LDH release %ð Þ
¼ Sample absorption−TritonX 100absorption
TritonX 100 absorption−HBSS : HEPES absorption
 
 100
Permeability Studies
Calu-3 cell monolayers were grown on Transwell® perme-
able supports and themonolayer integrity routinely confirmed
by transepithelial electrical resistance (TEER) measurements.
Cells with TEER values exceeding 500 Ωcm2 were used for
further experiments.
Permeability studies were performed in HBSS:HEPES
(25 mM, pH 7.4) at 37°C and 4°C. The cells were incubated
with 1.5 mL (basal) and 0.5 mL (apical) HBSS:HEPES for 1 h
prior to the experiment. The apical solution was then with-
drawn and a 0.25 mL solution of FITC-insulin (60 μg/mL) in
HBSS:HEPES added. To this, 0.25 mL of HBSS:HEPES or
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10, 2.0, 1, 0.2, 0.1, 0.02 mM Solutol® HS15 in
HBSS:HEPES was added. 100 μL samples from the
basolateral compartment were taken every 30 min for 3 h
thereafter, and replaced with the same amount of
HBSS:HEPES. Collected samples were then analysed using
a Dynex MFX microtiter plate fluorometer with ex/em 485/
518 nm, slit width 2.5 nm (ex/em). The procedure was re-
peated using human growth hormone (25 μg/mL), albumin
(50 μg/mL) and IgG (10 μg/mL).
Permeability is expressed as the apparent permeability
coefficient (Papp), calculated using the following equation:
Papp ¼ ΔQΔt
 
 1
A Co
 
Where Papp is the apparent permeability in cm/s, A is the
diffusion area of the cell layer (cm2), Co is the initial permeant
concentration and ΔQ/Δt is the permeability rate [amount
(μg) traversing the cell layers over time (s)]. Permeability rate
was determined from the gradient of the amount of
transported solute vs time plot.
Effect on TEER
Calu-3 cells were cultured as polarised monolayers on
Transwell® inserts, as described above. Baseline TEER was
measured following replacement of culture medium with
25 mM HBSS:HEPES buffer and equilibration for 60 min.
Solutol® HS15 solutions were prepared in HBSS:HEPES
buffer (25 mM, pH 7.4) at 5.0, 1.0, 0.5, 0.1, 0.05 and
0.01 mM and applied to the apical surface for 3 h, with
measurements taken at predetermined time points (every
30 min). Samples were then removed and replaced with the
culture medium and TEERmeasurements taken at 24-h time
point.
Ch i t o s a n s o l u t i o n a t 0 . 0 0 3% w/ v i n 2 - (N -
morpholino)ethanesulfonic acid (MES)-buffered HBSS
(10 mM, pH 6.0) was used as a comparison, given its well-
documented absorption enhancing effects (13, 14). Results are
presented as values relative to changes in TEER during ap-
plication of the respective control (MES-buffered HBSS,
pH 6.0).
Zonula Occludens (ZO-1) Immunostaining
Confluent Calu-3 cell layers grown on Transwell® inserts
were incubated with 0.1 and 5.2 mM Solutol® HS15 in
HBSS:HEPES for 3 h. HBSS:HEPES (25 mM, pH 7.4) alone
was used as the negative control. Following the incubation,
cells were fixed with 4%w/v paraformaldehyde at room tem-
perature for approximately 10 min, washed with PBS and
permeabilised using Triton X-100 (3.1 mM in PBS) for ap-
proximately 10 min. After a series of washing stages using
PBS, 1%w/v bovine serum albumin (BSA) in PBS solution
was applied for approximately 1 h and then removed.
Thereafter, BSA/PBS solution was replaced with mouse,
anti-human ZO-1 (primary) antibody, in 1%w/v BSA/PBS,
at 10 μg/ml and incubated for 1 h. Cells were washed and
FITC-labelled goat, anti-mouse (secondary) antibody, diluted
according to manufacturer’s instructions in 1%w/v BSA/
PBS, was applied for 1 h. Each insert was then washed with
PBS extensively and the filter membrane excised and
mounted (using DABCO mounting medium) on glass slides
for confocal imaging. Cells were imaged using a Leica TCS
SP2 system mounted on a Leica DMIRE2 inverted
microscope.
Effect of Solutol® HS15 on the Distribution of F-Actin
Cytoskeleton
Calu-3 cells grown to confluence on Transwell® inserts as
described above, were incubated in the presence and absence
of Solutol® HS15 (5.2 mM and 0.1 mM) for 3 h at 37°C.
Following the incubation cells were fixed with paraformalde-
hyde at room temperature for approximately 10 min, washed
with PBS and permeabilised using Triton X-100 (3.1 mM in
PBS) for approximately 10 min. After a series of washing
stages using PBS, 1%w/v bovine serum albumin (BSA, in
PBS) was applied for approximately 1 h. Thereafter, a
0.17 μM Alexa Fluor-546 Phalloidin in 1%w/v BSA solution
was applied to each well and incubated for 20 mins, following
the manufacturer’s instructions. Following incubation, each
insert was extensively washed with PBS and filter membrane
excised and mounted (using DABCO mounting medium) on
glass slides for confocal imaging. Cells were imaged using a
Leica TCS SP2 system mounted on a Leica DMIRE2
inverted microscope.
Effect of Solutol® HS15 on K562 Cell Internalisation
of FM2-10 Probe
The effect of Solutol® HS15 on the rate of cellular
internalisation of FM2-10 dye was determined in K562 cell
suspensions. FM2-10 fluorescence emission increases upon
membrane incorporation and has been previously applied to
measure endocytosis, i.e. the kinetics of plasma membrane
internalisation (15), where endocytic vesicle formation can be
determined bymeasuring the changes in FM2-10 fluorescence
intensity as a function of time. Approximately 2.5×l06 K562
cells/ml RPMI medium were pelleted by centrifugation at
1,000 rpm for 5 min, and the supernatant was removed.
The cells were then washed and re-suspended once with sterile
phosphate buffered saline (PBS). The cells were pelleted by
centrifugation at 13,000 rpm for another 30 s. The superna-
tant was removed and the cell pellet re-suspended in 3 ml
PBS. Thereafter, 100 μL of the cell suspension was added to
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each well of a 96-well plate and incubated at 37°C for
10 min. Solutions of FM2-10 (200 nM) and Solutol® HS15
(10 mM) were prepared in PBS and incubated at 37°C.
Optima software was programmed to inject, firstly Solutol®
HS15, and secondly, FM2-10. The concentrations of
Solutol® HS15 solutions applied were 5.2, 1.0, 0.52, 0.1
and 0.01 mM (N=3, n=6), with the final concentration of
FM2-10 at 200 nM for each of the experiments. Fluorescence
(exCitation 530 nm, emission 590 nm) was measured using a
FLUROstar Optima microplate reader (BMG Labtech,
Germany).
Fluorescence changes of FM2-10 were measured over 1 h
(every 24 s) following sample application. Fluorescence chang-
es over 1 h of FM2-10 alone, K562 cells with FM2-10,
Solutol® HS15 alone and FM2-10 with Solutol® HS15 were
used as controls in this experiment. Percent membrane endo-
cytosis rates per minute were calculated by obtaining the
gradient of the line of a fluorescence vs time (min) plot,
dividing by the intercept and multiplying by 100 following
the addition of both Solutol® HS15 and FM2-10. This was
done for each concentration tested. To obtain the desired time
range the fluorescence values were collected (from the time
interval desired) and the gradient obtained then %
endocytosis/ minute was calculated (as above).
RESULTS
Solutol® HS15 Critical Micelle Concentration
and Micelle Size
The critical micellar concentration (CMC) of Solutol® HS15
in biologically relevant aqueous media was determined using
the pyrene 1:3 normalisation assay, typically used in the field
to confirm the CMC of surfactants (16, 17). Fig. 2 illustrates
the CMC of Solutol® HS15 in deionised water, PBS
(167 mM), as well as in HBSS:HEPES (25 mM), which was
subsequently used for cell studies. The CMC values reside in
the concentration range of 0.06 and 0.1 mM Solutol® HS15
for all media used.
The hydrodynamic diameters of the micelles formed by
Solutol® HS15 in deionised water, HBSS:HEPES or PBS
solutions, are shown in Table I. The micellar diameter was
found to be in the range 11–15 nm but most often within 12–
14 nm, with no significant differences in the diameter within
the concentration range (0.1 to 104.0 mM) or at the temper-
atures tested (4, 25 and 37°C).
Effect of Solutol® HS15 on Cell Viability
Figure 3a summarises data from the MTS assay, employed to
assess the effect of Solutol® HS15 on the viability of lung
derived Calu-3 and A549, as well as intestinal Caco-2 cells. A
general decline in cell metabolic activity is seen for all three
tested cell lines as the concentration of Solutol® HS15 solu-
tion is increased. A concentration-dependent effect is also seen
for LDH release from the cells (Fig. 3b).
The concentrations of Solutol® HS15 (mM) at which cell
viability (assumed to be proportional to metabolic activity and
inversely proportional to LDH release) is equal to 50% (EC50
values) are reported in Fig. 3c. These generally lie in the order
of 6.5–10.2 mM solutions, whereby for Calu-3 cells EC50
(mM) values are statistically greater when compared to
Caco-2 and A549 cell lines, indicating higher tolerance to
Solutol® HS15 toxicity.
Fig. 2 Normalisation of pyrene emission peaks 1:3 to determine the CMC
of Solutol® HS15 in deionised water, HBSS:HEPES (25 mM) and PBS
(162.7 mM). Profiles for 2 μM final pyrene solution are shown. Normalised
values presented as mean values±SD of N=3, n=4.
Table I Hydrodynamic Particle Diameter of Solutions of Solutol® HS15 in
Filtered Deionised Water, in HBSS:HEPES (25 mM) and in Phosphate Buffer
Saline (PBS). Dynamic Light Scattering Measurements Performed at 4, 25 and
37°C. Values Presented As Mean Hydrodynamic Diameter±SD, n=4
Concentration
(mM)
Temperature Average hydrodynamic diameter±SD (nm)
Deionised water HBSS:HEPES PBS
0.10 4°C 11.8±2.2 11.1±3.9 14.6±2.8
25°C 12.8±3.2 13.1±2.9 12.9±1.9
37°C 13.8±4.6 12.9±3.2 12.9±4.1
1.00 4°C 12.9±3.7 12.1±3.9 13.8±3.1
25°C 13.6±3.9 13.1±3.8 13.2±3.1
37°C 14.4±4.8 13.2±3.1 14.6±4.9
10.40 4°C 14.5±4.9 13.8±2.4 13.5±4.0
25°C 12.9±4.1 13.8±3.4 13.1±3.8
37°C 13.6±4.5 13.8±3.9 14.1±3.9
104.00 4°C 13.7±2.5 13.8±3.9 12.9±3.2
25°C 12.9±3.9 12.8±2.9 13.5±3.2
37°C 13.8±3.3 13.6±4.2 13.1±2.6
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Effect of Solutol® HS15 on the Permeability
of the Model FITC-Insulin Across Calu-3 Layers
The impact of Solutol®HS15 treatment on the apical to basal
permeability of FITC-insulin, expressed as Papp, across
polarised Calu-3 layers at 37 and 4°C, and measured over a
period of 3 h, is illustrated in Table II. The concentrations of
Solutol® HS15 employed possess toxicities below EC50
values, as listed in Fig. 3c.
The data in Table II demonstrate that Solutol® HS15
promotes the apical-to-basolateral translocation of a model
protein (insulin) across Calu-3 monolayers when applied at
37°C. Apparent permeability (Papp) values increase signifi-
cantly at concentrations of 0.52 mM and higher when com-
pared to the control (buffer). At the same permeability-
enhancing concentrations the experiment performed at 4°C
shows significantly lower Papp values, relative to 37°C
conditions. Furthermore there was no statistically significant
increase in insulin permeability in the presence of Solutol®
HS15, relative to the respective control, at 4°C.
Solutol® HS15 promotion of transepithelial transport test-
ed with other ‘model biotherapeutics’ is shown in Table III.
The data display a clear correlation between Papp values and
molecular weight, where, relative to the control, Solutol®
HS15 treated cells show a statistically significant increase in
permeability towards lower molecular weight permeants (5–
22 kDa) and an absence of a statistically significant increase in
permeability of proteins with larger molecular weight, namely
albumin and IgG (P>0.05 relative to control).
Effect of Solutol® HS15 on Transepithelial Electrical
Resistance (TEER) of Calu-3 Cell Layers
TEER vs time profiles for application of Solutol® HS15 to
polarised Calu-3 cell layers, in comparison to chitosan solu-
tion as a ‘classical’ permeability enhancer (6, 13), are shown in
Fig. 4. Results are presented as % decrease in TEER relative
to controls.
Following the application of Solutol® HS15 solutions,
minimal reduction in TEER was observed during the initial
3-h incubation, apart from the highest applied concentration
(5.2 mM), which is different compared to the TEER profile of
cell monolayers treated with chitosan solution where a steep
initial reduction in TEER values is evident. Following remov-
al of Solutol® HS15 and chitosan solutions and cell ‘recovery’
in culture medium, TEER reversal to a value close to the
baseline point is seen for chitosan at 24-h time point. On the
contrary, with Solutol® HS15 treatment TEER values are
lower relative to both baseline value and the value at the 3-h
sample incubation point.
Fig. 3 Effect of Solutol® HS15 on Calu-3, Caco-2 and A549 cells assessed by metabolic activity (a) and LDH assays (b). Solutol® HS15 was used at
concentrations above and below the Critical Micelle Concentration (Fig. 2). Data expressed as relative metabolic activity and presented as the mean±SD with
N=3 and n=4. Data to summarize Solutol® HS15 concentrations that cause 50% reduction in cell viability (EC50, mM) and LDH leakage in tested cell lines
shown in table (c). Statistical analysis: MTS assay, EC50 P values: Calu-3 to Caco-2<0.05, Caco-2 to A549>0.05 and Calu-3 to A459>0.05. LDH assay EC50 P
values; Calu-3 to Caco-2<0.05, Caco-2 to A549>0.05 and Calu-3 to A459<0.05 conducted using t-test. Overall statistical difference between each test
conducted for MTS and LDH P value<0.05, conducted using one-way ANOVA.
Table II Apical to Basolateral Permeability of FITC-Insulin in the Presence Of
Increasing Concentrations of Solutol® HS15 Across Polarised Calu-3 Cell
Monolayer Performed at 37°C and 4°C
Concentration
(mM)
Papp at 37°C
(×10−6 cm/s)
Papp at 4°C
(×10−6 cm/s)
Control 2.27±0.44 0.26±0.04
0.01 2.41±0.52 0.25±0.02
0.10 2.61±0.20 0.26±0.016
0.52 3.01±0.6 (*) 0.25±0.04
1.00 4.09±1.21 (**) 0.26±0.07
5.20 6.08±1.93 (***) 0.26±0.02
Permeability expressed as mean Papp, values±SD (N=3, n=4). * P=0.01 ,
** P=0.0021 and *** P=0.0001
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Distribution of ZO-1 and F-Actin Following Incubation
With Solutol® HS15
Confocal micrographs of Calu-3 layers following Solutol®
HS15 treatment at concentrations below and above the
CMC and immunostained for ZO-1 and F-actin distribution
are shown in Fig. 5. ZO-1, a junctional protein, normally
presents a ‘chicken wire-like’ distribution that resides closer
to the apical region of the Calu-3 monolayer. This wire-like
structure can be seen in control cells and appears to be
retained when Calu-3 cells are treated with solutions of
Solutol® HS15 below the CMC (0.01 mM). However, the
ZO-1 pattern becomes faintly distorted in places when Calu-3
monolayers are treated Solutol® HS15 above the CMC (1.00
and 5.20 mM). The change in ZO-1 appearance with
Solutol®HS15 is different to the dramatic re-distribution that
follows from Calu-3 treatment with chitosan (6).
In the absence of Solutol®HS15 (control) F-actin organises
around the periphery of the epithelial cells, which is consistent
with existing literature (13, 18). F-actin morphology appears
unaltered by the application of Solutol® HS15 at the concen-
tration below its CMC (0.01 mM). However, application of
concentrations which demonstrated an enhancement in the
permeability of insulin (Table II: 1.00 and 5.2 mM) appears to
rearrange the ‘normal’ distribution of F-actin from the cell
periphery towards the cell cytosol (arrows).
Effect of Solutol® on FM2-10 Recycling Rates
FM2-10 is a membrane dye which is normally used to inves-
tigate endocytosis and exocytosis rates, in particular the rate of
endocytic vesicle movement through the cell (15, 19). The
probe is believed to reversibly bind to the outer leaflet of the
cell membrane (and increases in fluorescence intensity) and,
during endocytosis, locates within the membrane of endocytic
vesicle (19). FM2-10 was employed in this experiment to
investigate the effect of Solutol® HS15 on membrane endo-
cytosis rate. The data in Fig. 6a depict the effect of Solutol®
HS15 on FM-210 fluorescence intensity changes vs time in a
suspension of K562 cells based on the previous demonstration
that the increase in fluorescence intensity as a function of time
corresponds to the fraction ofmembrane being internalised via
endocytosis per unit of time (15, 20). The profiles obtained
illustrate a gradual increase in fluorescence with time for all
tested samples, relative to respective control, whereby the
effect (slope of the curve) is generally dependent on the con-
centration of Solutol® HS15 applied to the cells.
Further analysis of the data, by calculating the endocytosis
rate (%/min) from FM2-10 fluorescence changes within 10–
60 and 35–60 min time periods, is shown in Fig. 6b. The
endocytosis rates (%/min) in the presence of Solutol®
HS15 at concentrations above the CMC are significantly
higher than the control (cells and FM2-10 applied alone).
Interestingly, endocytosis rate (%/min) increases significantly
after 35–40 min of the Solutol® HS15 application.
Table III The Effect of Solutol® HS15 (Applied as 5.2 mM Solution in
HBSS:HEPES, 25 mM, pH 7.4) on the Permeability In Polarised Calu-3 Cell
Layers To Different Sized Proteins Employed as ‘Model Proteins’. Experiment
Conducted at 37°C
Permeant Mw
(kDa)
Papp Control
(×10−6 cm/s)
Papp Solutol® HS15
(×10−6 cm/s)
Papp enhancement
ratio
Insulin 5.8 2.27±0.44 6.08 (*)±1.93 2.68
hGH 22 1.81±0.51 4.30 (*)±1.26 2.30
Albumin 66 1.26±0.16 1.28±0.26 1.02
IgG 150 0.59±0.19 0.59±0.16 1.00
Data expressed as Papp of permeant alone and following co-application with
Solutol® HS15 (5.2 mM). (*) indicates statistically significant deviation,
P<0.001, N=3 and n=4
Fig. 4 Effect of Solutol® HS15 solutions on TEER values of polarized Calu-3 monolayers. Baseline Calu-3 monolayer TEER values were measured using HBSS:
HEPES following replacement of culture medium with HBSS: HEPES buffer and equilibration for 45 min. Tested samples removed after 3 h and cells incubated in
culture medium. Data represented as mean% TEER, relative to control±SD (N=3, n=4). Each tested Solutol®HS15 concentration significantly deviated from
one another, P<0.05. All Solutol® HS15 samples significantly deviated from Chitosan sample (P<0.001), conducted using one-way ANOVA.
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DISCUSSION
Further to a previous demonstration that CriticalSorb™ pro-
motes macromolecular drug permeation across the nasal and
intestinal mucosa and promising results from Phase I clinical
trials (8), this work investigated possible mechanism (s)
governing the action of Solutol® HS15 (its principal compo-
nent) as a permeability enhancer.
Initially, our work confirmed that Solutol® HS15, as ex-
pected from its molecular structure and composition (Fig. 1)
Fig. 5 Confocal micrographs with
XZ stack showing distribution of
junctional complex protein ZO-1
(left) and F-actin morphology (right)
distribution in polarized Calu-3
monolayers following application of
Solutol® HS15. White arrows
highlight changes in F-actin
distribution following Solutol®
HS15 application. ZO-1 (green)
was immunostained with mouse,
anti-human ZO-1 (primary)
antibody then with FITC-labelled
goat, anti-mouse (secondary)
antibody. F-actin was
immunostained with Alexafluor
546-labelled phalloidin (red) and
nuclei blue. Scale bar represents
25 μm and ‘cross hair’ represents
region for Z stack analysis. ImageJ
(1.47 K) image software was used
to create the overlay images from
raw series images.
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(21), forms 13–14 nm sized micelles in aqueous media above
its CMC (0.06–0.1 mM) at 37°C. The work further demon-
strated that the CMC and the size of Solutol® HS15 micelles
do not appear to be influenced by the composition of biolog-
ically relevant buffers (HBSS:HEPES and PBS) or the tem-
perature examined, which is in accordance with the behaviour
of non-ionic surfactants (22). This is of importance in under-
standing Solutol® HS15’s behaviour in further in vitro biolog-
ical studies conducted in this work.
Application of Solutol® HS15 solutions to a panel of
epithelial cell cultures showed that, in general, Solutol®
HS15 possesses a relatively high EC50 (6.5–10.2 mM) when
compared to other reported surfactant-like absorption en-
hancers, including sodium cholate (2.04–4.94 mM) and
Tween 80 (5.41–6.49 mM) tested in human nasal epithelial
cells via the MTT assay (23), as well as alkyl glycosides
(Dodecyl-β-D-maltoside 0.64 mM; Tridecyl-β-D-maltoside
0.34 and Tetradecyl-β-D-maltoside 0.26 mM) in Calu-3 cells
tested by the MTS and LDH assays (4). It should be pointed
out that the LDH assay revealed a Solutol® HS15 concen-
tration dependent release of the intracellular enzyme (lactate
dehydrogenase) in the surrounding buffer, hence providing an
initial indication on altered permeability of the cell membrane
in tested cells.
Considering the cellular toxicity of Solutol® HS15 in the
context of its CMC, both LDH and MTS assays indicated
appearance of toxic effects at concentrations above the CMC.
In comparison, toxicity of other non-ionic surfactants (e.g.
Triton X-100 and monolaurin) towards epithelial cells has
been reported to occur around their CMC and attributed to
their ‘non-selective’ action involving cell membrane
destabilisation. This is in contrast to the behaviour of cationic
surfactants which show significant toxicity at concentration far
below their CMC (24).
Enhancement in permeability across Calu-3 cell layers for
insulin (as a model protein) by Solutol® HS15 shows
concentration dependence, when measured at 37°C, reaching
a 2.7-fold increase in permeability at 5.2 mMSolutol®HS15.
It is worth mentioning that, at 5.2 mM, Solutol® HS15 is
cytotoxic to about 30% of Calu-3 cells (and >40% in case of
Caco-2 and A549 cells), which highlights that there is some
overlap in concentrations that are toxic and those that in-
crease permeability. This overlap in toxicity and permeability
enhancement, as observed in vitro, is also apparent with other
classes of absorption enhancers, including chitosan (6).
However, as with other absorption enhancers, whether the
absorption enhancing effects outweigh any potential toxic
effects should be carefully evaluated in animal studies. In this
regard, Solutol®HS15 has demonstrated a promising toxicity
profile (8).
However, when tested at 4°C this concentration-
dependent permeability enhancement was absent for all
Solutol® HS15 concentrations applied. Low temperature
permeability assays are routinely performed to (i) lower the
fluidity of the plasma membrane and (ii) decrease ATP hy-
drolysis (25) thus in fact reducing both passive and active
transcellular transport. In this study such temperature depen-
dent behaviour could imply that the mechanism of Solutol®
HS15 permeability enhancement potentially involves effects
on plasma membrane as well as active intracellular processes.
To discuss temperature dependence of Solutol® HS15
permeability enhancement, it should be noted that the lowest
concentration at which a statistically significant increase in
insulin permeability occurs corresponds to 0.52 mM solution,
a concentration significantly above the CMC (0.06–0.1 mM).
The fact that permeability enhancement, as well as toxicity,
occur at concentrations above the CMC suggests that the
presence of Solutol® HS15 surfactant molecules aggregated
into micellar structures is contributing to the observed effects.
Reports on similar surfactant behaviour suggested that in such
a situation surfactant monomers incorporate into the cell
membrane (a phenomenon responsible for the enhancement
Fig. 6 (a) FM2-10 recycling rate performed on K562 cells in the presence and absence of Solutol®HS15. Fluorescence intensity was measured every 24 s, over
1 h. (b) FM2-10% endocytosis/min performed on K562 cells, over 60 min and 35–60 min (N=3, n=6). ***=<0.001, **=<0.005, *=< 0.05).
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in membrane permeability), the membrane gradually be-
comes saturated with monomer molecules and this occurs in
the presence of micelles in solution which act as reservoirs (26,
27) to provide monomers which interact with the membrane.
The data derived in the present work show that Solutol®
HS15 exists in a micellar form in the tested buffers at both 4
and 37°C, but that its permeability effect is only seen at the
higher temperature. At 37°C the cell membrane could be
expected to exist in a ‘fluid state’ (28) and the partitioning of
Solutol® HS15 monomers within the membrane bilayer
could perturb the packing order of phospholipids (29, 30),
enhancing membrane permeability via promoting disorder
within the cell membrane bilayer (31). At lower, 4°C temper-
ature, the cell membrane is believed to exist in a more ordered
‘solid state’ (32) which may reduce partitioning of Solutol®
HS15 monomers into the membrane bilayer (33) to a level
insufficient to perturb the packing order and enhance the
permeability. Considering the molecular structure of
Solutol® HS15 (Fig. 1), the presence of hydroxyl group in
the alkyl chain, as well as existence of di-esters, would be
expected to cause significant disorder in the phospholipid
bilayer packing following its insertion. It is generally accepted
that changes in the hydrophobic region of a surfactant mole-
cule, for instance substitution of hydrogen in alkyl chain with
hydrophilic groups, induces disordering within the phospho-
lipid bilayer/membrane of cells (34, 35).
Interestingly, if Solutol® HS15 enhances the permeability
of macromolecules by the perturbation in the cell membrane,
this effect appears to be dependent on the drug’s molecular
weight, showing preference for lower molecular weight mac-
romolecules. Apparent permeability rates in the presence of
Solutol® HS15 are comparable to the control for tested
proteins exceeding 60 kDa, but significantly higher for mole-
cules below this molecular weight threshold (Table III).
Comparison of TEER vs time profiles for Solutol® HS15
and a classical permeability enhancer which affects the epi-
thelial tight junctions, namely chitosan (6, 7, 13), illustrates
significant differences in their behaviour (Fig. 4). Application
of Solutol® HS15 at a range of concentrations below and
above its CMC to polarised cell monolayer does not appear to
mimic a TEER vs time profile typically seen for chitosan (or
EDTA) (6, 36), which involves a steep initial decrease in
TEER values following chitosan application, with reversal/
recovery over time (24 h) following its removal. Solutol®
HS15 treatment resulted in gradual decrease in TEER values
during a 3-h exposure, which was non-reversible within 24-h
of the recovery period even at low concentrations.
Furthermore, changes in the distribution of ZO-1 protein
following immunostaining (Fig. 5) were not observed to follow
a fashion documented previously for chitosan (6, 13). The
‘chicken wire’-like structure became somewhat ‘distorted’
when cell monolayers were treated with permeability enhanc-
ing concentrations of Solutol® HS15 (1.00 and 5.20 mM), in
comparison to a considerable effect in case of chitosan appli-
cation at permeability enhancing concentrations (6). These
data would indicate that the primary effect of Solutol®
HS15 in promoting drug transport across cell membranes
may not via an effect on the epithelial tight junction complex
unlike a classical tight junction opening enhancer.
Immunostaining for a cytoskeleton structure protein, F-
actin, however illustrates that its distribution appears to be
significantly rearranged, a phenomenon also described with
chitosan (13). F-actin appears to disband from the periphery
(typical peri-junctional pattern seen in the control sample) of
the cell towards the cytosol ‘interior’ when Solutol® HS15
was applied at its permeability-enhancing concentrations
(>0.52 mM) (Fig. 5). F-actin cellular distribution is considered
to be related to, and dependent on, the local lipid environ-
ment of the cell membrane (37, 38). The alterations in cell
distribution of F-actin following application of non-ionic sur-
factants as permeability enhancers have previously been re-
ported (18). It would be therefore conceivable that if Solutol®
HS15 molecules were to incorporate into the cell membrane
bilayer, a change in local lipid environment would conse-
quently affect F-actin binding to the membrane, as reported
previously (28, 38). The observed distortions in the appear-
ance of ZO-1 protein may be a consequence of F-actin re-
distribution, as per their intimate association within cytoskeletal
structure (39), and in that way may, to some extent, contribute
to paracellular transport.
To investigate in more detail the effect of Solutol® HS15
on the cell membrane, we employed the FM2-10 probe as a
fluorescent styryl dye normally used to gain an insight into
fluid phase endocytosis rates (40), which is believed to be
directly related to lipid asymmetry (20) and thus will report
on changes in the lipid composition of plasma cell membrane.
The probe was co-applied to K562 cell suspension in the
presence of increasing concentrations of Solutol® HS15.
Data obtained indicate an increased incorporation of FM2-
10 into cell membrane structures (slope in fluorescence vs time
profiles in Fig. 6a) when co-applied with Solutol® HS15
relative to the control (application of FM2-10 alone). The
extent of this effect (gradient of the curve expressed as endo-
cytosis rate) appears to be a concentration dependent phe-
nomenon, whereby the endocytosis rate increases with an
increase in Solutol® HS15 concentration. Interestingly, the
increase in endocytosis also appears to be time dependent,
whereby the kinetics of endocytosis significantly increases after
35 min incubation time (Fig. 6b) for the Solutol® HS15
concentrations shown to enhance permeability (Table II)
and alter F-actin morphology (Fig. 5). The concentration
and time dependent effects of Solutol® HS15 on the rate of
fluid phase endocytosis are most likely due to the concentra-
tion of Solutol® HS15 required to change the composition of
the membrane resulting in increased vesicle formation and the
time needed for such compositional changes to occur.
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Solutol® HS15 has previously been investigated as a nasal
absorption enhancer in rats (Male Sprague Dawley) (8), in
non-human primates, in human nasal Phase 1 studies and in
Caco-2 cell culture studies (10). In the acute and chronic rat
studies, Solutol® HS15 was found to be a potent and non-
toxic nasal absorption enhancer for the delivery of human
growth hormone (hGH) with a bioavailability of 49.9% in the
first 2 h after application relative to a subcutaneous adminis-
tration of hGH. The concentration of Solutol® HS15 used in
the rat study was 10%w/v, significantly higher than that used
in the present cell culture study (5.2mM; equivalent to ~0.5%
w/v). Furthermore, a 6 months once daily repeat dose toxicity
study on Solutol®HS15 in rats after nasal application showed
no treatment related effects even at the highest dose level
(10% Solutol® HS15 solution). This highlights the generally
accepted difference in expression of toxicity in in vivo studies in
animal models and cell cultures. The present study confirmed
the ability of Solutol® HS15 to enhance the transport of hGH
across Calu-3 monolayers at much lower concentrations than
used in in vivo studies.
Brayden et al. reported Solutol® HS15 (100 μM) to en-
hance both [14C]-mannitol and FD-4 in a paracellular and
transcellular fashion across Caco-2 monolayers, isolated rat
ileum and rat colonic mucosae (10). In relation to these
studies, our study found Solutol® HS15 to enhance the per-
meability model drugs in a concentration- and time-
dependent fashion, as well as size selective manner, which
operated through primarily a transcellular mechanism of ac-
tion based on its ability to interact with the plasma membrane
of cells.
CONCLUSIONS
This study investigates the potential mechanism (s) of action of
Solutol®HS15, the principal component of CriticalSorb®, as
a mucosal absorption enhancer. The work initially confirms
surfactant-like behaviour of Solutol® HS15, which forms
approximately 13–14 nm sized micelles in aqueous media.
The effect of permeability enhancing concentrations of
Solutol® HS15 on epithelial tight junction differs, as judged
by curve profiles in TEER vs time measurements and pattern
in ZO-1 staining, from a ‘classical’ tight junction opening
agent, chitosan. The permeability enhancing effect may be
connected to Solutol’s partitioning into and affecting cellular
membrane structure at physiological temperature. This con-
sequently causes changes in F-actin distribution, which are
reflected in tight junction structure via ZO-1 and F-actin
association. However, this effect does not appear lead to a
significant loss in ZO-1 structure, as seen for chitosan at
permeability enhancing concentrations. Considering its effect
on cellular membrane, the use of FM2-10 probe demonstrates
increased endocytosis rate in the presence of Solutol®
HS15 at permeability enhancing concentrations. The time
dependence of this event, i.e. a significant increase in the
endocytosis rate after approximately 35–40 min, may suggest
that saturation of the plasma membrane with partitioning
Solutol® HS15 molecules is required prior to a sufficient
membrane structure disruption/fluidity change. The study,
in summary, indicates that Solutol® HS15 effects on the cell
membrane may play a major role in its transepithelial perme-
ability enhancement where future work would need to provide
detailed understanding of these interactions and resultant
downstream biological processes leading to increased mem-
brane permeability and transport across the epithelial cell
layer.
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